USE OF PIM KINASE INHIBITORS TO AUGMENT THE EFFICACY OF ANTI-CD20 ANTIBODY-BASED THERAPIES IN HEMATOLOGIC MALIGNANCIES AND NON-MALIGNANT CONDITIONS

摘要

The present invention relates to the use of PIM kinase inhibitors in the treatment of hematological malignancies and non-malignant conditions in combination therapy with anti-CD20 antibody. Moreover, the invention discloses combination therapy pharmaceutical composition comprising as an active ingredients an effective amount of PIM inhibitor, and an effective amount of anti-CD20 antibody and pharmaceutically acceptable excipients.